A157: Macrophage Activation Syndrome‐like Illness Due to an Activating Mutation in NLRC4. Issue 11 (March 2014)
- Record Type:
- Journal Article
- Title:
- A157: Macrophage Activation Syndrome‐like Illness Due to an Activating Mutation in NLRC4. Issue 11 (March 2014)
- Main Title:
- A157: Macrophage Activation Syndrome‐like Illness Due to an Activating Mutation in NLRC4
- Authors:
- Canna, Scott
de Jesus, Adriana Almeida
Deng, Zuoming
Gouni, Sushanth
Marrero, Bernadette
Brooks, Stephen
Dimattia, Michael
Liu, Yin
Huang, Yan
Plass, Nicole
Chapelle, Dawn C.
Montealegre, Gina
Benseler, Susanne
Laxer, Ronald M.
Goldbach‐Mansky, Raphaela - Abstract:
- Abstract : Background/Purpose: Macrophage Activation Syndrome (MAS) is a life‐threatening systemic inflammatory disorder of unknown etiology. While MAS has no known genetic basis, clinical similarity with a genetic disorder of impaired cytotoxicity known as primary Hemophagocytic Lymphohistiocytosis (HLH) has suggested shared pathogenesis. In contrast, other investigations have suggested innate immune dysregulation drives MAS. Methods: We performed detailed clinical, genetic, and immunologic evaluation of a patient with early onset, recurrent MAS‐like disease including whole exome sequencing and analyses of serum cytokines, whole blood transcription, and stimulated monocyte and macrophage responses. We subsequently tested the effects of a de novo mutation in transfection experiments with a monocytic cell line. Results: We identified a 7 year‐old female with recurrent episodes of fever, splenomegaly, transaminitis, pancytopenia, occasional evanescent rash, and massive hyperferritinemia since 6 months of age. Her Natural Killer cell function was normal, and she had no mutations in genes associated with HLH or hereditary periodic fever syndromes. Whole exome sequencing identified a de novo missense mutation in a highly conserved area in the nucleotide‐binding region of the inflammasome component NLRC4. Interleukin (IL)‐1b, Interferon a2, and particularly IL‐18 were elevated in the patient's peripheral blood even during clinical quiescence. The patient's monocytes produced moreAbstract : Background/Purpose: Macrophage Activation Syndrome (MAS) is a life‐threatening systemic inflammatory disorder of unknown etiology. While MAS has no known genetic basis, clinical similarity with a genetic disorder of impaired cytotoxicity known as primary Hemophagocytic Lymphohistiocytosis (HLH) has suggested shared pathogenesis. In contrast, other investigations have suggested innate immune dysregulation drives MAS. Methods: We performed detailed clinical, genetic, and immunologic evaluation of a patient with early onset, recurrent MAS‐like disease including whole exome sequencing and analyses of serum cytokines, whole blood transcription, and stimulated monocyte and macrophage responses. We subsequently tested the effects of a de novo mutation in transfection experiments with a monocytic cell line. Results: We identified a 7 year‐old female with recurrent episodes of fever, splenomegaly, transaminitis, pancytopenia, occasional evanescent rash, and massive hyperferritinemia since 6 months of age. Her Natural Killer cell function was normal, and she had no mutations in genes associated with HLH or hereditary periodic fever syndromes. Whole exome sequencing identified a de novo missense mutation in a highly conserved area in the nucleotide‐binding region of the inflammasome component NLRC4. Interleukin (IL)‐1b, Interferon a2, and particularly IL‐18 were elevated in the patient's peripheral blood even during clinical quiescence. The patient's monocytes produced more of a number of inflammatory cytokines in response to stimulation than controls, while monocyte‐derived macrophages specifically over‐produced IL‐1b and IL‐18. Transfection of THP1 monocytes with a plasmid bearing a mutant NLRC4 construct resulted in increased cell death and IL‐1b production versus a wild‐type plasmid. The patient showed short‐term clinical improvement and ability to wean steroids with recombinant IL‐1 receptor antagonist (IL‐1ra) therapy. Conclusion: While NLRP3 inflammasome hyperactivity has been implicated in the pathogenesis of a variety of autoinflammatory conditions, our data suggest that a mutation in the ADP binding domain of NLRC4 can result in MAS‐like disease. This mutation may destabilize NLRC4's auto‐inhibited conformation by altering ADP binding (1 ), resulting in enhanced/spontaneous activation and pathogenic production of IL‐1b and IL‐18. NLRC4 hyperactivity represents a novel mechanism of MAS/HLH pathogenesis. … (more)
- Is Part Of:
- Arthritis & rheumatology. Volume 66:Issue 11(2014)supplement
- Journal:
- Arthritis & rheumatology
- Issue:
- Volume 66:Issue 11(2014)supplement
- Issue Display:
- Volume 66, Issue 11 (2014)
- Year:
- 2014
- Volume:
- 66
- Issue:
- 11
- Issue Sort Value:
- 2014-0066-0011-0000
- Page Start:
- S203
- Page End:
- S203
- Publication Date:
- 2014-03
- Subjects:
- Arthritis -- Periodicals
Rheumatism -- Periodicals
616.72 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2326-5205 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/art.38583 ↗
- Languages:
- English
- ISSNs:
- 2326-5191
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1733.820000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19570.xml